Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.74 |
| ▸ | ESR1 | P03372 | 10/20 | 0.67 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.62 |
| ▸ | NQO1 | P15559 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | VKORC1 | Q9BQB6 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8934606 | 0.93 | CYP19A1 (0.80) | CYP19A1ESR1ESR2NQO1NPC1 | |
| SCHEMBL5428058 | 0.89 | CYP19A1 (0.81) | CYP19A1ESR1ESR2NQO1NPC1 | |
| SCHEMBL5146155 | 0.89 | CYP19A1 (0.65) | CYP19A1ESR1ESR2NQO1NPC1 | |
| SCHEMBL4640144 | 0.87 | ESR1 (0.64) | CYP19A1ESR1ESR2NQO1NPC1 | |
| SCHEMBL14428676 | 0.85 | CYP19A1 (0.68) | CYP19A1ESR1ESR2NPC1ALDH1A1 | |
| SCHEMBL13183965 | 0.85 | CYP19A1 (0.67) | CYP19A1ESR1ESR2NPC1ALDH1A1 | |
| SCHEMBL8934551 | 0.84 | VKORC1 (0.66) | CYP19A1ESR1ESR2NQO1VKORC1 | |
| SCHEMBL5139700 | 0.84 | ESR1 (0.84) | CYP19A1ESR1ESR2ERAP1KDM4E | |
| SCHEMBL25079562 | 0.81 | ESR1 (0.70) | CYP19A1ESR1ESR2NPC1CYP2C9 | |
| SCHEMBL14428675 | 0.81 | ESR1 (0.63) | CYP19A1ESR1ESR2ERAP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191343-A1 | 4-((4-(2-Azaperhydroepinylethoxy)phenyl)methyl)-3-2(2,4-dichlorophenyl)-7-hydroxychromen-2-one, pharmaceutically acceptable salts thereof and methods of use therewith | SIGNAL PHARMACEUTICALS, LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070191343-A1 | 4-((4-(2-Azaperhydroepinylethoxy)phenyl)methyl)-3-2(2,4-dichlorophenyl)-7-hydroxychromen-2-one, pharmaceutically acceptable salts thereof and methods of use therewith | SIGNAL PHARMACEUTICALS, LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070123511-A1 | Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer | SIGNAL PHARMACEUTICALS LLC | 2007-05-31 | — | — | US | disclosed |
| EP-1450812-A4 | USE OF BENZOPYRANONES FOR TREATING OR PREVENTING A PRIMARY BRAIN CANCER OR A BRAIN METASTASIS | SIGNAL PHARM INC (US) | 2007-03-28 | — | — | EP | disclosed |
| US-7148252-B2 | Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis | SIGNAL PHARMACEUTICALS, LLC (US) | 2006-12-12 | — | — | US | disclosed |
| EP-1246814-B1 | COMPOUNDS AND METHODS FOR MODULATION OF ESTROGEN RECEPTORS | SIGNAL PHARM INC (US) | 2005-02-16 | — | — | EP | disclosed |
| EP-1450812-A2 | USE OF BENZOPYRANONES FOR TREATING OR PREVENTING A PRIMARY BRAIN CANCER OR A BRAIN METASTASIS | Signal Pharmaceuticals, Inc. (US) | 2004-09-01 | — | — | EP | disclosed |
| EP-1140889-B1 | COMPOUNDS AND METHODS FOR MODULATION OF ESTROGEN RECEPTORS | SIGNAL PHARM INC (US) | 2003-08-27 | — | — | EP | disclosed |
| US-20030149025-A1 | Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis | SIGNAL PHARMACEUTICALS, INC. | 2003-08-07 | — | — | US | disclosed |
| WO-2003028652-A2 | USE OF BENZOPYRANONES FOR TREATING OR PREVENTING A PRIMARY BRAIN CANCER OR A BRAIN METASTASIS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-04-10 | — | — | WO | disclosed |
| US-6372739-B1 | COUMARONE DERIVATIVES FOR DRUGS | SIGNAL PHARMACEUTICALS, INC. | 2002-04-16 | — | — | US | disclosed |
| US-6331562-B1 | SELECTIVELY MODULATE ESTROGEN RECEPTOR-BETA ACTIVITY; INHIBIT CYTOKINES SUCH AS INTERLEUKIN-6 | SIGNAL PHARMACEUTICALS, INC. | 2001-12-18 | — | — | US | disclosed |
| EP-1140889-A2 | COMPOUNDS AND METHODS FOR MODULATION OF ESTROGEN RECEPTORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6291456-B1 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, INC. | 2001-09-18 | — | — | US | disclosed |
| WO-2000039120-A2 | COMPOUNDS AND METHODS FOR MODULATION OF ESTROGEN RECEPTORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149025-A1 | Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis | RB1, FOXK1, SKP1 | CYP19A1 879/4885ESR1 2470/4885ESR2 1390/4885 |
| US-20070123511-A1 | Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer | BRCA1, RB1, TP53 | CYP19A1 23/4885ESR1 343/4885ESR2 515/4885 |
| US-20070191343-A1 | 4-((4-(2-Azaperhydroepinylethoxy)phenyl)methyl)-3-2(2,4-dichlorophenyl)-7-hydroxychromen-2-one, pharmaceutically acceptable salts thereof and methods of use therewith | CYP3A43, CYP2D6, CYP2J2 | CYP19A1 44/4885ESR1 697/4885ESR2 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.